8-K: Shattuck Labs Reports Q2 2026 Results, Advances DR3 Pipeline

Shattuck Labs announced strong Q2 2026 financial results, highlighting positive Phase 1 data for SL-325 and a cash runway extending into 2029.

Summary

• Shattuck Labs reported its financial results for the second quarter ended June 30, 2026.
• The company announced positive Phase 1 clinical trial results for its lead candidate, SL-325, demonstrating a favorable safety profile and durable DR3 blockade.
• The RECEPTIVE-CD1 Phase 2b clinical trial for SL-325 in Crohn's disease is expected to initiate in Q3 2026.
• Shattuck also announced SL-846, a new bispecific antibody candidate, with Phase 1 data expected in 2027.
• The company strengthened its balance sheet, ending the quarter with approximately $208.3 million in cash and cash equivalents, expected to fund operations into 2029.
• R&D expenses for Q2 2026 were $11.7 million, and G&A expenses were $4.5 million.
• The net loss for Q2 2026 was $15.2 million, or $0.12 per share.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong clinical data for SL-325 and a robust cash position extending runway into 2029, indicating good progress and financial stability.

Positives

• Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile and a potentially best-in-mechanism immunogenicity profile.
• SL-325 showed durable DR3 blockade of TL1A binding, potentially supporting quarterly maintenance dosing.
• The RECEPTIVE-CD1 Phase 2b clinical trial for SL-325 in Crohn's disease is on track to initiate in Q3 2026.
• The company announced SL-846, a lead bispecific product candidate, with Phase 1 data expected in 2027.
• Strengthened balance sheet with approximately $208.3 million in cash and cash equivalents and short-term investments as of June 30, 2026.
• Cash position is expected to fund operations into 2029.
• Net loss per share improved to $0.12 in Q2 2026 from $0.24 in Q2 2025.

Negatives

• Net loss for the quarter ended June 30, 2026, was $15.2 million, an increase from $12.5 million in the prior year's quarter.
• R&D expenses increased to $11.7 million in Q2 2026 from $8.7 million in Q2 2025.

Risks

• Global macroeconomic conditions and related volatility.
• The initiation, progress, and expected results of preclinical studies and clinical trials, including timing and costs.
• The company's ability to enroll patients in clinical trials.
• The unpredictable relationship between preclinical and clinical study results.
• The company's ability to advance product candidates into and successfully complete nonclinical and clinical trials.
• The timing or likelihood of regulatory filings and approvals.
• The scope of intellectual property protection.
• Liquidity and capital resources, and the time period over which current capital resources will fund operations.

Future Outlook

The company expects its current cash and cash equivalents and short-term investments of approximately $208.3 million as of June 30, 2026, to fund operations into 2029. This guidance excludes potential additional capital, business development transactions, or increased clinical development costs.

Management Comments

• "The Phase 1 clinical data for SL-325 has checked all of the boxes and positions SL-325 as a potentially winning antibody in the TL1A/DR3 axis heading into Phase 2 clinical development," said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
• "The RECEPTIVE-CD1 Phase 2b clinical trial in Crohns disease is on track to initiate in the third quarter, and is designed to establish the efficacy profile of SL-325 across three dose levels, both at induction and at maintenance time points."
• "As we expected, clinical proof of concept for the TL1A/DR3 axis is now emerging outside of IBD. We are pleased to see this continued momentum for the class, and we believe that blocking DR3 will prove more efficacious than blocking TL1A across any indication where TL1A is implicated."

Industry Context

StockSavvy.ai notes that Shattuck Labs is operating in the highly competitive and innovation-driven clinical-stage biotechnology sector, focusing on inflammatory and immune-mediated diseases. The company's emphasis on DR3 blocking antibodies places it in a niche with emerging therapeutic potential, particularly as clinical proof of concept for the TL1A/DR3 axis gains traction across the industry.

Comparison to Industry Standards

• The immunogenicity profile of SL-325 (3.7% of participants developing anti-drug antibodies) appears favorable compared to some biologic therapies, though direct industry-wide benchmarks for this specific metric are complex to isolate without detailed comparative trial data.
• The projected cash runway into 2029 for a clinical-stage biotech company of this size is generally considered strong, providing a significant advantage in drug development timelines.
• The development of a half-life extended bispecific antibody (SL-846) aligns with industry trends towards more convenient dosing regimens and targeted therapies.

Related Party Transactions

• Investment in related party of $1,000,000 as of June 30, 2026, and December 31, 2025.

Stakeholder Impact

• Shareholders: Positive impact from strong clinical data for SL-325 and extended cash runway, potentially increasing long-term value. Capital raises provide funding but dilute ownership.
• Employees: Continued operations and R&D funding provide job security and opportunities for growth within the company.
• Creditors: The company's strong cash position and financial stability reduce short-term credit risk.

Next Steps

• Initiate the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in patients with moderately-to-severely active Crohn's disease in Q3 2026.
• Present preclinical data for SL-846 at UEG Week, October 17-20, 2026.
• Initiate a Phase 1 healthy volunteer clinical trial of SL-846 and report initial data in 2027.
• Participate in the 21st Annual Wells Fargo Healthcare Conference (September 8-10, 2026).
• Participate in Citi's 2026 Biopharma Back to School Conference (September 9-10, 2026).
• Participate in the Cantor Global Healthcare Conference (September 9-11, 2026).

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' based on the filing. While the clinical data for SL-325 is promising and the cash runway is robust, the company is still in the clinical development phase with significant risks and long timelines ahead. The net loss continues, and the success of upcoming trials is not guaranteed. The capital raises provide necessary funding but also indicate dilution. Investors should await further clinical trial results before considering a more aggressive stance.

Keywords

DR3 blocking antibodies, SL-325, Crohn's disease, biotechnology, clinical-stage, inflammatory diseases, immune-mediated diseases, SL-846